Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9% – Here’s Why

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) shot up 7.9% during mid-day trading on Tuesday . The company traded as high as $16.69 and last traded at $16.62. Approximately 185,957 shares changed hands during trading, a decline of 74% from the average daily volume of 720,033 shares. The stock had previously closed at $15.40.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on KLRA shares. Leerink Partners began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price target on the stock. William Blair initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating for the company. Wall Street Zen lowered Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Jefferies Financial Group began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $48.00 target price on the stock. Finally, Evercore assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Price Performance

The business’s 50 day simple moving average is $18.94. The firm has a market cap of $2.20 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). As a group, analysts expect that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. California State Teachers Retirement System bought a new stake in shares of Kailera Therapeutics during the 2nd quarter worth approximately $309,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $24,233,000. Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics in the second quarter valued at $64,308,000. Finally, Atlas Venture Life Science Advisors LLC bought a new position in shares of Kailera Therapeutics in the second quarter valued at $113,923,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.